Advances in clinical laboratory tests for inflammatory bowel disease

Clinica Chimica Acta

Volumn 335, Issue 1-2, 2003, Pages 9-20

  Nakamura, Robert M ^a,b   Matsutani, Mariko ^b   Barry, Mary ^b  

^a SCRIPPS CLINIC   (United States)

^b Prometheus Laboratories   (United States)

Author keywords

CD (Crohn's disease); IBD (inflammatory bowel disease); pANCA in IBD; Serologic antibody markers; UC (ulcerative colitis)

Indexed keywords

ANTIBODY; NEUTROPHILIC CYTOPLASMIC ANTIBODY; UNCLASSIFIED DRUG;

BACTEROIDES; CLINICAL FEATURE; CROHN DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; ENTERITIS; ESCHERICHIA COLI; GENE; GENETIC ANALYSIS; GENETIC VARIABILITY; HEPATITIS; HUMAN; IMMUNOASSAY; LABORATORY TEST; MYCOBACTERIUM; NOD2 GENE; PATHOGENESIS; PATHOPHYSIOLOGY; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PSEUDOMONAS FLUORESCENS; REVIEW; SACCHAROMYCES CEREVISIAE; SEROLOGY; ULCERATIVE COLITIS;

BACTERIA (MICROORGANISMS); BACTEROIDES; BACTEROIDES CACCAE; COCCOIDEA; CORYNEBACTERINEAE; PSEUDOMONAS; PSEUDOMONAS FLUORESCENS; SACCHAROMYCES; SACCHAROMYCES CEREVISIAE;

EID: 0242285713     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(03)00286-9     Document Type: Review

References (87)

1. Nakamura R.M., Barry M. Serologic markers in inflammatory bowel disease (IBD). Med. Lab. Obs. 33:2001;8-15.
2. Crohn B.B., Ginsberg L., Oppenheimer G.D. Regional Ileitis, a pathological and clinical entry. JAMA. 99:1932;1323.
3. Rosenberg I.H. Crohn's disease. Wyngaarden J.B., Smith L.H. Jr. Cecil textbook of medicine. 7th ed. 1982;711-719 Saunders, Philadelphia, PA.
4. Satsangi J., Parkes M., Louis E., Hashimoto L., Kato W., Welsh K.et al. Two-stage genome-wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7, and 12. Nat. Genet. 14:1996;199-202.
5. Andres P.E., Friedman L.S. Epidemiology and the natural course of inflammatory bowel disease. Inflamm. Bowel Dis. 28:1999;255-281.
6. Baldassano R.N., Piccoli D.A. Inflammatory bowel disease in pediatric and adolescent patients. Inflamm. Bowel Dis. 28:1999;445-459.
7. Hodgson H.J.F. Ulcerative colitis versus Crohn's disease - one disease or two? Allan R.N., Rhodes J.M., Hanauer S.B., Keighley M.R.B., Alexander-Williams J., Fasio V.W. Inflammatory bowel diseases. 3rd ed. 1997;343-347 Churchill Livingstone, New York.
8. Vasiliauskas E.A., Plevy S.E., Landers C.J., Binder S.W., Ferguson D.M., Yang A.et al. Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup. Gastroenterology. 110:1996;1810-1819.
9. Seidman E.G. Inflammatory bowel diseases. Roy C., Silverman A., Alagille D. Pediatric gastrointestinal disease. 4th ed. 1996;585-605 Mosby, St. Louis.
10. Evan C.M., Beattie R.M., Walker-Smith J.A. Inflammatory bowel disease in childhood. Allan R.N., Rhodes J.M., Hanauer S.B., Keighley M.R.B., Alexander-Williams J., Fazio V.W. Inflammatory bowel diseases. 3rd ed. 1997;343-347 Churchill Livingstone, New York.
11. Moum B., Ekbom A., Vato M.H., Aadland E., Sauer J., Lygen I.et al. Inflammatory Bowel disease: re-evaluation of the diagnosis in a prospective population, based study in southeastern Norway. Gut. 1997;328-332.
12. Seidman E., Deslandres C. Pitfalls in the diagnosis and management of pediatric IBD. Hadziselimovic F., Herzog B. Inflammatory bowel disease and recurrent abdominal pain. Falk Symposium 91:1997;111-120 Kluwer Academic Publishing, Lancaster, England.
13. Targan S., Murphy L.K. Serologic and mucosal markers of ulcerative colitis and Crohn's disease. Implications of pathophysiology for diagnosis. Scholmerich J., Kruis W., Goebell H.et al. Inflammatory bowel disease - pathophysiology as a basis of treatment. 1993;283-286 Kluwer Academic Publishing, Dordrecht.
14. Rothstein R.D. Irritable bowel syndrome. Adv. Gastroenterol. 84:2000;1247-1257.
15. Ringel Y., Sperber A.D., Drossman D.A. Irritable bowel syndrome. Annu. Rev. Med. 52:2001;319-330.
16. Manning A.P., Thompson W.G., Heaton K.W. Toward a positive diagnosis of the irritable bowel. BMJ. 2:1978;653.
17. Thompson W.G., Longstreet C.E., Drossman D.A. Functional bowel disorders and functional abdominal pain. Gut. 2:1999;1143.
18. Olden K.W. Diagnosis of irritable bowel syndrome. Gastroenterology. 122:2002;1701-1714.
19. Drossman D.A., Corazziari E., Talley M.J.et al. Rome II. The functional gastrointestinal disorders. 2nd ed. Diagnosis, pathophysiology and treatment: a multinational consensus. 2000;Diagnon Assoc. McLean, VA.
20. Abreu M.T., Vasiliaskas E.A., Kam L.Y., Dubinsky M.C. Use of serologic tests in Crohn's disease. Clin. Perspect. Gastroenterol. 20:2001 (May/June);155-164.
21. Robertson D.J., Grimm I.S. Inflammatory bowel disease of the elderly. Gastroenterol. Clin. North Am. 30:2001;409-426.
22. Farrell R.J., Banerjee S., Peppercorn M.A. Recent advances in inflammatory bowel disease. Crit. Rev. Clin. Lab. Sci. 38:2001;33-108.
23. Papadakis K.A., Targen S.A. Current theories of the causes of inflammatory bowel disease. Gastroenterol. Clin. North Am. 28:1999;283-296.
24. Watts D.A., Satsangi J. The genetic jigsaw of inflammatory bowel disease. Gut. 50(Suppl. III):2002;iii31-iii36.
25. Judge T., Lichenstein G.R. The MOD 2 gene and Crohn's disease: Another triumph for molecular genetics. Gastroenterology. 122:2002;826-828.
26. Rotter J.I., Yang H. Delineating the major aetiological risk factors for IBD: the genetic susceptibilities. Scholmerich J., Krus W., Goebell H.et al. Inflammatory bowel diseases - pathophysiology as a basis of treatment. 1993;9-18 Kluwer Academic Publishing, Dordrecht.
27. Satsangi J., Jewell D.P., Rosenberg W.M.C.et al. Genetics of inflammatory bowel disease. Gut. 35:1994;696-700.
28. Yang H., Rotter J.L. The genetics of inflammatory bowel disease: genetic predispositions, disease markers, and genetic heterogeneity. Targan S.R., Shanahan F. Inflammatory bowel disease from bench to bedside. 1994;32-64 Williams and Wilkins, Baltimore.
29. Bonen D., Cho J. The genetics of inflammatory bowel disease. Gastroenterology. 124:2003;521-536.
30. Satsangi J., Parkes M., Jewell D.P., Bell J.I. Genetics of inflammatory bowel disease. Clin. Sci. (Lond.). 94(5):1998 (May);473-478.
31. Cho J. Update on inflammatory bowel disease genetics. Curr. Gastroenterol. Rep. 2(6):2000 (Dec);434-439.
32. Mirza M.M., Fisher S.A., King K., Cuthbert A.P., Hampe J., Sanderson J. et al. Genetic evidence for interaction of the 5q31 cytokine locus and the CARD15 gene in Crohn disease. Am. J. Hum. Genet. 72(4):2003 (Apr);1018-1022.
33. Yang H., Ohmen J.D., Ma Y., Bentley L.E., Targan S.R., Fischel-Ghoddian W.et al. Additional evidence of linkage of Crohn's disease and a putative locus on chromosome 12. Genet. Med. 1:1999;194-198.
34. Toyoda H., Wang S.J., Yang H.Y., Redford A., Magalong D., Tyan D.et al. Distinct Association of HLA Class II genes with inflammatory bowel disease. Gastroenterology. 104:1993;741-748.
35. Ogura Y., Inohara N., Benigo A., Chen F.F., Yamaoka S., Nunez G. Nod2, a Nod2/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB. J. Biol. Chem. 276:2001;4812-4818.
36. Ogura Y., Bonen D.K., Inohara N., Nicolase D.L., Chen F.F., Ramos R.et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature. 411:2001;603-606.
37. Hugot J.P., Chamaaillard M., Zouali H., Lesage S., Cezard J.P., Belaiche J.et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 411:2001;599-603.
38. Abreu M.T., Taylor K.D., Lin Y.C., Hang T., Gaiennie J., Landers C.J.et al. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Gastroenterology. 123:2002;679-688.
39. Roussomoustakaki M., Satsangi J., Welsh K., Louis E., Fanning G., Targan S.et al. Genetic markers may predict disease behavior in patients with ulcerative colitis. Gastroenterology. 112(6):1997 (Jun);1845-1853.
40. Papo M., Quer J.C., Gutierrez C., Broch M., Casellas F., Pastor R.M.et al. Genetic heterogeneity within ulcerative colitis determined by an interleukin-1 receptor antagonist gene polymorphism and antineutrophil cytoplasmic antibodies. Eur. J. Gastroenterol. Hepatol. 11(4):1999 (Apr);405-407.
41. Vijgen L., Van Gysel M., Rector A., Thoelen I., Esters N., Ceelen T.et al. Interleukin-1 receptor antagonist VNTR-polymorphism in inflammatory bowel disease. Genes Immun. 3(7):2002 (Nov);400-406.
42. Andres P.G., Freedman L.S. Epidemiology and the natural course of inflammatory bowel disease. Inflamm. Bowel Dis. 28:1999;255-281.
43. Cohavy O., Harth G., Horwitz M., Eggena M., Landers C., Sutton C.et al. Identification of a novel mycobacterial histone H1 homologue (HupB) as an antigenic target of pANCA monoclonal antibody and serum immunoglobulin A from patients with Crohn's disease. Infect. Immun. 67:1999;6510-6517.
44. Sutton C.L., Kim J., Yamane A., Dalwadi H., Wei B., Landers C.et al. Identification of a novel bacterial sequence associated with Crohn's disease. Gastroenterology. 119(1):2000 (Jul);254-257
45. Sutton C.L., Kim J., Yamane A., Dalwadi H., Wei B., Landers C.et al. Identification of a novel bacterial sequence associated with Crohn's disease. Gastroenterology. 120(4):2001 (Mar);1066-1067.
46. Landers C.J., Cohavy O., Misra R., Yang H., Lin Y.C., Braun J.et al. Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens. Gastroenterology. 123:2002 (Sep);689-699.
47. Cohavy O., Bruckner D., Gordon L.K., Misra R., Wei B., Eggena M.E.et al. Colonic bacteria express an ulcerative colitis pANCA-related protein epitope. Infect. Immun. 68:2000;1542-1548.
48. Janowitz H.D., Croen E.C., Sachar D.B. The role of the fecal stream in Crohn's disease. An historical and analytic review. Inflamm. Bowel Dis. 4:1998;29-39.
49. Wei B., Dalwadi H., Gordon L.K., Landers C., Bruckner D., Targan S.R.et al. Molecular cloning of a Bacteroides caccae TonB-linked outer membrane protein identified by an inflammatory bowel disease marker antibody. Infect. Immun. 69:2001;6044-6054.
50. Vasiliauskas E. Serum immune markers in inflammatory bowel disease. Gastroenterol. Endosc. News. 1997 (October);1-5.
51. Ruemmele F.M., Targan S.R., Levy G., Dubinsky M., Braun J., Seidman E.G. Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology. 115:1998;822-829.
52. Targan S.R. The utility of ANCA and ASCA in inflammatory bowel disease. Banks P., Present D. Inflammatory bowel disease. vol. 5:1999;61-63 Lippincott William and Wilkins, Baltimore, MD.
53. Vasiliauskas E.A., Kam L.Y., Karp L.C., Giaennie J., Yang H., Targan S.R. Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut. 47:2000;487-496.
54. Dubinsky M., Ofman J.J., Urman C., Targan S.R., Siedman E.G. Clinical utility of serodiagnostic testing in suspected pediatric inflammatory bowel disease. Am. J. Gastroenterol. 46:2001;758-765.
55. Shanahan F. Neutrophil autoantibodies in ulcerative colitis: familial aggregation and genetic heterogeneity. Gastroenterology. 103(2):1992;707-711.
56. Saxon A., Shanahan F., Landers C., Ganz T., Targan S.R. A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. J. Allergy Clin. Immunol. 86:1990;202-206.
57. Vermeire S., Joossens S., Peeters M., Monsuur F.et al. Comparative study of ASCA (anti-Saccharomyces cerevisiae antibody) assays in inflammatory bowel disease. Gastroenterology. 120:2001;827-833.
58. Stocker M., Otte S., Ulrich D., Normann H.et al. Autoimmunity to pancreatic juice in Crohn's disease. J. Gastroenterol. 22(Suppl. 139):1987;41-52.
59. Seibold P., Weber H., Jenss H., Wiedmann K.H. Antibodies to a trypsin sensitive pancreatic antigen in chronic inflammatory bowel disease: specific markers for a subgroup of patients with Crohn's disease. Gut. 32:1991;1192-1197.
60. Seibold P., Mork H., Tanza S., Muller A., Holzhuter P., Weber P.et al. Pancreatic autoantibodies in Crohn's disease: a family study. Gut. 40:1997;4484-4811.
61. Linskens R.K., Mallant-Hent R.C., Groothuismink A., Bakker-Jonges L.E., van de Merwe J.P., Hooijkaas H.et al. Evaluation of serological markers to differentiate between ulcerative colitis and Crohn's disease: pANCA, ASCA and agglutinating antibodies to anaerobic coccoid rods. Eur. J. Gastroenterol. Hepatol. 14:2002;1013-1017.
62. Wensinck F., Van de Merwe J.P. Serum agglutinins to Eubacterium and Peptostreptococcus species in Crohn's and other diseases. J. Hyg. 87:1981;13-24.
63. Gross W.L., Cseronok E., Helmchen U. Antineutrophil cytoplasmic autoantibodies, autoantigens, and systemic vasculitis. APMIS. 103(2):1995 (Feb);81-97.
64. Bylund D.J., McCallum R.M. Idiopathic vasculitis and antineutrophilic cytoplasmic antibodies. Nakamura R.M., Keren D.E., Bylund D.J. Clinical and laboratory evaluation of human autoimmune diseases. 2002;213-231 American Society of Clinical Pathologists Press, Chicago, IL. Chap. 13.
65. Conn D.L., Hander G.G., O'Duffy J.D. Vasculitis and related disorders. Kelly W.N., Harris E.D. Jr., Ruddy S., Sledge C.B. Vasculitis and related disorders. 4th ed. 1993;1077-1102 Saunders, Philadelphia, PA.
66. Falk R.J., Jennette J.C. Anti-neutrophilic cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and cresentric glomerulonephritis. NEJM. 318:1988;1651-1657.
67. Jennette J.C., Falk R.J. Vasculitis. Rose N.R., Mackay I.R. The autoimmune diseases. 3rd ed. 1998;705-724 Academic Press, San Diego, CA.
68. Jennette J.C., Hoidal J.R., Falk R.J. Specificity of antineutrophilic cytoplasmic antibodies for proteinase 3. Blood. 75:1990;2263-2264.
69. Savige J.A., Paspaliaris B., Silvestrini R., Davies D., Nikoloutsopoulos T., Sturgess A.et al. A review of immunofluorescent patterns associated with antineutrophil cytoplasmic antibodies (ANCA) and their differentiation from other antibodies. J. Clin. Pathol. 51(8):1998 (Aug);568-575.
70. Faber V., Elling A.P. Leucocyte-specific antinuclear factor in patients with Felty's syndrome, rheumatoid arthritis, systemic lupus erythematosis and other diseases. Acta Med. Scand. 179:1967;257-267.
71. Neilsen H., Wiik A., Elmgreen J. Granulocyte specific antinuclear antibodies in ulcerative colitis. Acta Pathol. Microbiol. Immunol. Scand. 91:1983;23-26.
72. Muller-Ladner U., Gross V., Andus T., Gschwendtner H., Roth M., Caesar I.et al. Distinct patterns of immunoglobulin classes and IgG subclasses of autoantibodies in patients with inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol. 8:1996;579-584.
73. Billing P., Tahir S., Cifin B., Gagne G., Cobb L., Targan S.R.et al. Nuclear localization of the antigen detected by ulcerative colitis-associated perinuclear antineutrophil cytoplasmic antibodies. Am. J. Pathol. 147:1995;979-987.
74. Eggen S.M., Cohavy O., Parseghian M.H., Hamkalo B.A., Clemens D., Targan S.R.et al. Identification of histone H1 as a cognate antigen of the ulcerative colitis-associated marker antibody pANCA. J. Autoimmun. 14(1):2000 (Feb.);83-97.
75. Sobajima J., Ozaki S., Uesugi S., Osakada H.F., Shirakawa H., Yoshida M.et al. Prevalence and characterization of perinuclear anti-neutrophil cytoplasmic antibodies (pANCA) directed against HMG1 and MG2 in ulcerative colitis (UC). Clin. Exp. Immunol. 111:1998;402-407.
76. Sobajima J., Ozaki S., Uesugi H., Osakada F., Inoue M., Fukuda Y.et al. High mobility group (HMG) non-histone chromosomal proteins HMG1 and HMG2 are significant target antigens of perinuclear anti-neutrophil cytoplasmic antibodies in autoimmune hepatitis. Gut. 44:1999;867-873.
77. Terjung B., Spengler U., Sauerbruch T., Worman H. "Atypical pANCA" in IBD and hepatobiliary disorders react with a 50 kilodalton nuclear envelope protein of neutrophils and myeloid cell lines. Gastroenterology. 119:2000;310-322.
78. Eggena M., Targan S.R., Iwanczyk L., Vidrich A., Gordon L.K., Braun J. Phage display cloning and characterization of an immunogenetic marker (perinuclear anti-neutrophil cytoplasmic antibody) in ulcerative colitis. J. Immunol. 156:1996;4005-4011.
79. Vasiliauskas E.A., Plevy S.E., Landers C.J., Binder S.W., Ferguson D.M., Yang H.et al. Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup. Gastroenterology. 110:1996;1810-1819.
80. Vidrich A., Lee J., James E., Cobb L., Targan S. Segregation of pANCA antigenic recognition by DNase treatment of neutrophils: ulcerative colitis, Type I autoimmune hepatitis, and primary sclerosing cholangitis. J. Clin. Immunol. 15(6):1995;293-299.
81. Hardarson S., LaBrecque D.R., Mitros F.A., Neil G.A., Goeken J.A. Antineutrophil cytoplasmic antibody in inflammatory bowel and hepatobiliary diseases. High prevalence in ulcerative colitis, primary sclerosing cholangitis, and autoimmune hepatitis. Am. J. Clin. Pathol. 99:1993;277-281.
82. Sendid B., Colombel J.F., Jacquinot P.M., Faille C., Fruit J., Corlot A.et al. Specific antibody response to oligomannosidic epitopes in Crohn's disease. Clin. Diagn. Lab. Immunol. 3:1996;219-226.
83. Sendid B., Quinton J.F., Charrier G.et al. Anti-Saccharomyces cerevisiae mannan antibodies in familial Crohn's disease. Am. J. Gastroenterol. 93:1998;1306-1310.
84. Quinton J.F., Sendid B., Reumaux D.et al. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut. 42:1998;788-791.
85. Rose S., Lentz J., Walsh M. Clinical evaluation of a new immunodiagnostic assay system for inflammatory bowel disease. Am. J. Gastroenterol. 93(9):1998;A597.
86. Sandborn W.J., Loftus E.V., Colombel J.F., Fleming K.A., Seibold F., Homburger H.A.et al. Evaluation of serologic disease markers in a population based cohort of patients with ulcerative colitis and Crohn's disease. Inflamm. Bowel Dis. 7:2001;192-201.
87. Duerr R.H., Targan S.R., Landers C.J., Sutherland L.R., Shanahan F. Anti-neutrophil cytoplasmic antibodies in ulcerative colitis. Comparison with other colitides/diarrheal illnesses. Gastroenterology. 100:1991;1590-1596.